NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
Logicbio gives Astra a novel gene-editing technology at a bargain price.
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
Bristol Myers Squibb/Johnson & Johnson and Bayer will soon get more hints about whether their Eliquis and Xarelto follow-ons can cut it.